Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript
Vaxart, Inc. (OTC:VXRT) Shareholder/Analyst Call November 18, 2025 4:30 PM EST Company Participants Steven Lo - President, CEO & Director Jeroen Grasman - CFO, Principal Accounting Officer & Principal Financial Officer Edward Berg - Senior VP & General Counsel Sean Tucker - Senior VP & Chief Scientific Officer James Cummings - Chief Medical Officer Conference Call Participants David Carey - Finn Partners, Inc. Presentation Operator Greetings, and welcome to the Vaxart Stockholder Fireside Chat Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript
Vaxart, Inc. (OTC:VXRT) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Edward Berg - Senior VP & General Counsel Steven Lo - President, CEO & Director James Cummings - Chief Medical Officer Sean Tucker - Senior VP & Chief Scientific Officer Jeroen Grasman - CFO, Principal Accounting Officer & Principal Financial Officer Conference Call Participants Cheng Li - Oppenheimer & Co. Inc., Research Division Nabeel Nissar - Jefferies LLC, Research Division Presentation Operator Greetings, and welcome to the Vaxart Business Update and Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript
Vaxart, Inc. (OTC:VXRT) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Edward B. Berg - Senior VP & General Counsel James F.
VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates
VAXART, INC. (VXRT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09.
Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript
Vaxart, Inc. (NASDAQ:VXRT ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Ed Berg - SVP and General Counsel Steven Lo - CEO James Cummings - CMO Sean Tucker - Founder and CSO Phillip Lee - CFO Conference Call Participants Cheng Li - Oppenheimer Mayank Mamtani - B. Riley Securities Liang Cheng - Jefferies Operator Greetings.
Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript
Vaxart, Inc. (NASDAQ:VXRT ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Ed Berg - SVP and General Counsel Steven Lo - CEO James Cummings - CMO Sean Tucker - Founder and CSO Phillip Lee - CFO Ray Stapleton - CTO Conference Call Participants Cheng Li - Oppenheimer Liang Cheng - Jefferies Operator Greetings and welcome to the Vaxart Business Update and Fourth Quarter and Full Year 2024 Financial Results Conference call. A question-and-answer session will follow management's opening remarks.
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates
VAXART, INC. (VXRT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.10.
VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates
VAXART, INC. (VXRT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10.
Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript
Vaxart, Inc. (NASDAQ:VXRT ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Edward Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Officer James Cummings - Chief Medical Officer Sean Tucker - Senior Vice President and Chief Scientific Officer Phillip Lee - Chief Financial Officer Conference Call Participants Cheng Li - Oppenheimer Mayank Mamtani - B. Riley Securities Liang Cheng - Jefferies Operator Greetings and welcome to the Vaxart Business Update and Third Quarter 2024 Financial Results Conference Call.
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
Oppenheimer initiated coverage on Vaxart Inc. VXRT, an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines.
Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript
Vaxart, Inc. (NASDAQ:VXRT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Ed Berg - SVP & General Counsel Steven Lo - CEO Sean Tucker - Founder & Chief Scientific Officer James Cummings - Chief Medical Officer Phil Lee - CFO Conference Call Participants Elaine Kim - Cantor Fitzgerald Operator Greetings and welcome to the Vaxart Business Update and Second Quarter 2024 financial results, conference call, a question and answer session will follow management's opening remarks. Individual investors may submit written questions to IR at vaxart.com As a reminder, this conference is being recorded.
VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates
VAXART, INC. (VXRT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of $0.03.
